Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Non-Current Deferred Tax Liability (2019 - 2024)

Crinetics Pharmaceuticals (CRNX) has 1 years of Non-Current Deferred Tax Liability data on record, last reported at $9.8 million in Q4 2023.

  • For Q4 2023, Non-Current Deferred Tax Liability changed N/A year-over-year to $9.8 million; the TTM value through Dec 2023 reached $9.8 million, changed N/A, while the annual FY2023 figure was $9.8 million, N/A changed from the prior year.
  • Non-Current Deferred Tax Liability reached $9.8 million in Q4 2023 per CRNX's latest filing.
  • Across five years, Non-Current Deferred Tax Liability topped out at $9.8 million in Q4 2023 and bottomed at $9.8 million in Q4 2023.